Published: 2 March 2017
Publications
Recent Approvals of Medicines containing a New Active Ingredient
Prescriber Update 38(1): 15
March 2017
For period 16 October 2016 to 15 January 2017
| Trade Name (active ingredient)* | Dose form and strength | Therapeutic area |
|---|---|---|
| Brimica Genuair (aclidinium/eformoterol) | Powder for inhalation 340 mcg/12 mcg | Chronic obstructive pulmonary disease (COPD) |
| Entresto 24/26 (sacubitril/valsartan) | Film coated tablet 24.3 mg/25.7 mg | Chronic heart failure |
| Epclusa (sofosbuvir/velpatasvir) | Tablet 400 mg/100 mg | Chronic hepatitis C virus infection |
| Genvoya (cobicistat/ elvitegravir/emtricitabine/ tenofovir)† | Tablet 150 mg/150 mg/200 mg/10 mg | HIV-1 infection |
| Lynparza (olaparib) | Capsule 50 mg | Ovarian, fallopian tube or primary peritoneal cancer |
| Otezla (apremilast) | Film coated tablet, titration pack 10mg, 20mg, 30mg | Plaque psoriasis |
| Zepatier (elbasvir/grazoprevir) | Film coated tablet 50 mg/100 mg | Chronic hepatitis C virus infection (genotypes 1, 3, or 4) |
* New active ingredient shown in bold type
† The new active ingredient in Genvoya is tenofovir alafenamide
fumarate (TAF), which replaces tenofovir disoproxil fumarate (TDF) in the
related product Stribild.
The data sheets for currently marketed prescription medicines are published on the Medsafe website (www.medsafe.govt.nz/Medicines/infoSearch.asp).
